Fluralaner
4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide
También conocido como: Bravecto Plus · Fluralanerum
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Evidencia posológica v13 auditada
Evidencia estructurada para el cálculoOtodectes cynotis (extra-label)
Requiere verificación veterinaria
- once
NA
Contexto clínico obligatorio (1)
- Do not store fluralaner chewable tablets above 30°C (86°F) or topical solutions above 25°C (77°F). Store in the original packaging to protect from moisture. The topical solution is highly flammable. Keep away from heat, sparks, open flame, or other sources of ignition.
Sarcoptes scabiei var canis infestation (extra-label)
Requiere verificación veterinaria
- once
NA
Contexto clínico obligatorio (1)
- Do not store fluralaner chewable tablets above 30°C (86°F) or topical solutions above 25°C (77°F). Store in the original packaging to protect from moisture. The topical solution is highly flammable. Keep away from heat, sparks, open flame, or other sources of ignition.
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
El fluralaner es un ectoparasiticida sistémico del grupo de las isoxazolinas utilizado principalmente para el tratamiento y la prevención de infestaciones por pulgas y garrapatas en perros y gatos. Proporciona una duración de acción prolongada, que generalmente dura hasta 12 semanas por dosis.
Perla clínica: La formulación masticable oral para perros debe administrarse con comida para maximizar la absorción gastrointestinal. Utilizar con precaución en animales con antecedentes conocidos de convulsiones o trastornos neurológicos.
Mecanismo de acción
Fluralaner acts as an ectoparasiticide by antagonizing ligand-gated chloride channels.
It specifically targets channels gated by the neurotransmitter gamma-aminobutyric acid (GABA) and glutamate (GluCl) → blocks pre- and post-synaptic transfer of chloride ions across cell membranes → results in uncontrolled central nervous system activity and death of insects and acarines.
Seguridad y advertencias
Contraindicaciones
- Known hypersensitivity to fluralaner or any excipients
- Use with caution in dogs or cats with pre-existing epilepsy or seizure disorders
- Puppies less than 8 weeks of age or weighing less than 2 kg
- Kittens less than 11 weeks of age or weighing less than 1.2 kg
Efectos adversos
- Vomiting
- Diarrhea
- Lethargy
- Decreased appetite
- Application site reactions (erythema, pruritus, alopecia for topical forms)
- Rare neurological signs (muscle tremors, ataxia, seizures)
- Neurologic signs (tremors, ataxia, seizures - rare)
- Application site reactions (erythema, pruritus - topical forms)
Precauciones
Neurologic Warning: Isoxazolines have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures, even in animals without a prior history.
Ensure accurate dosing based on body weight. Do not break or divide chewable tablets.
Interacciones farmacológicas
Fluralaner is highly bound to plasma proteins and might theoretically compete with other highly bound drugs, though clinical significance is generally low.
Fluralaner is highly protein-bound and may theoretically compete with other highly bound drugs, though clinical significance is generally considered low.
Monitorización
- Efficacy of parasite control
- Signs of gastrointestinal upset
- Neurological status (especially in animals with a history of seizures)
- Adverse neurologic signs (tremors, ataxia, seizures)
Farmacocinética
Vida media
Absorción
Readily absorbed following oral administration in dogs when given with food. Topical formulations are absorbed systemically through the skin.
Distribución
Highly bound to plasma proteins. Distributes widely to tissues, particularly fat, which acts as a depot.
Metabolismo
Undergoes minimal hepatic metabolism.
Eliminación
Eliminated primarily unchanged in the feces via biliary excretion, with a very minor portion excreted in urine.
Sobredosis
Fluralaner is generally well tolerated. In safety studies, oral administration of up to 5 times the maximum recommended dose in dogs produced no severe adverse effects. Overdoses may increase the risk of gastrointestinal upset or transient neurological signs. Treatment is symptomatic and supportive.
Productos disponibles
Formulaciones
- Oral chewable tablets (dogs)
- Topical spot-on solution (dogs and cats)
- Topical spot-on solution with moxidectin (cats)
- Topical spot-on solution combined with moxidectin (cats)
Veterinario
- Bravecto chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg)
- Bravecto spot-on solution for dogs and cats (280 mg/ml)
- Bravecto Plus spot-on solution for cats (280 mg/ml fluralaner + 14 mg/ml moxidectin)
- Bravecto spot-on for dogs and cats (280 mg/ml)
- Bravecto Plus spot-on for cats (280 mg/ml fluralaner + 14 mg/ml moxidectin)
Estado regulador
FDA approved for flea and tick control.
POM-V
POM-V
Sin datos reguladores para: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Store at room temperature (below 30°C). Keep in original packaging to protect from moisture and light.
Información para el cliente
Administre el comprimido masticable a su perro durante o cerca del momento de la alimentación para asegurar que el medicamento se absorba correctamente. Este medicamento proporciona hasta 12 semanas de protección contra pulgas y garrapatas. Vigile a su mascota por si presenta molestias estomacales leves (vómitos o diarrea) después de la administración. Contacte a su veterinario de inmediato si observa temblores musculares, movimientos descoordinados o convulsiones.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.